Inotai A - Search Results

1

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary.

Inotai A, Abonyi-Tóth Z, Rokszin G, Vokó Z. Inotai A, et al. Value Health Reg Issues. 2015 Sep;7:1-8. doi: 10.1016/j.vhri.2015.03.020. Epub 2015 Apr 22. Value Health Reg Issues. 2015. PMID: 29698146 Free article.

2

Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods.

McQueen RB, Mendola ND, Jakab I, Bennett J, Nair KV, Németh B, Inotai A, Kaló Z. McQueen RB, et al. Among authors: inotai a. Pharmacoecon Open. 2023 Mar;7(2):217-228. doi: 10.1007/s41669-022-00376-w. Epub 2022 Nov 1. Pharmacoecon Open. 2023. PMID: 36316575 Free PMC article.

3

Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review.

Ágh T, Kovács G, Pawaskar M, Supina D, Inotai A, Vokó Z. Ágh T, et al. Among authors: inotai a. Eat Weight Disord. 2015 Mar;20(1):1-12. doi: 10.1007/s40519-014-0173-9. Epub 2015 Jan 9. Eat Weight Disord. 2015. PMID: 25571885 Free PMC article. Review.

4

Occurrence, Survival And Annual Cost of Colorectal-, Breast-, Prostate- and Lung Cancer in Hungary.

Inotai A, Abonyi-Tóth Z, Rokszin G, Voko Z. Inotai A, et al. Value Health. 2014 Nov;17(7):A553. doi: 10.1016/j.jval.2014.08.1809. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201806 Free article. No abstract available.

5

Osteoporotic fractures may impair life as much as the complications of diabetes.

Vokó Z, Gáspár K, Inotai A, Horváth C, Bors K, Speer G, Kaló Z. Vokó Z, et al. Among authors: inotai a. J Eval Clin Pract. 2017 Dec;23(6):1375-1380. doi: 10.1111/jep.12800. Epub 2017 Sep 12. J Eval Clin Pract. 2017. PMID: 28895276

6

Drug Policy in Hungary.

Inotai A, Csanádi M, Harsányi A, Németh B. Inotai A, et al. Value Health Reg Issues. 2017 Sep;13:16-22. doi: 10.1016/j.vhri.2017.06.003. Epub 2017 Aug 2. Value Health Reg Issues. 2017. PMID: 29073982 Free article.

7

Population-level norm values by EQ-5D-3L in Hungary - a comparison of survey results from 2022 with those from 2000.

Inotai A, Nagy D, Kaló Z, Vokó Z. Inotai A, et al. Qual Life Res. 2024 Sep;33(9):2417-2428. doi: 10.1007/s11136-024-03699-9. Epub 2024 Jun 5. Qual Life Res. 2024. PMID: 38839684 Free PMC article.

8

Need for multicriteria evaluation of generic drug policies.

Kaló Z, Holtorf AP, Alfonso-Cristancho R, Shen J, Ágh T, Inotai A, Brixner D. Kaló Z, et al. Among authors: inotai a. Value Health. 2015 Mar;18(2):346-51. doi: 10.1016/j.jval.2014.12.012. Epub 2015 Feb 11. Value Health. 2015. PMID: 25773570 Free article. Review.

9

[Assessment of the pharmaceutical expenditure in Hungary].

Inotai A, Merész G, Kaló Z. Inotai A, et al. Acta Pharm Hung. 2010;80(4):162-72. Acta Pharm Hung. 2010. PMID: 21404477 Hungarian.

10

Benefits of investment into modern medicines in Central-Eastern European countries.

Inotai A, Petrova G, Vitezic D, Kaló Z. Inotai A, et al. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):71-9. doi: 10.1586/14737167.2014.868314. Epub 2013 Dec 19. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 24350863 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters